Yue Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Wang has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Guan Wang
National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, School of Life Sciences, the Ministry of Education, Jilin University, Changchun, China.
3 shared publications - Shuangshuang Wu
Department of Pediatrics Hematology, Children’s Medical Center, The First Hospital of Jilin University, Changchun, China
3 shared publications - Yubin Ge
Department of Oncology, Wayne State University School of Medicine, Detroit, USA
3 shared publications Chunhuai Li
Department of Pediatric Hematology, The First Hospital of Jilin University, Changchun, PR China
2 shared publicationsFangbing Liu
National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, PR China
2 shared publicationsGuan Wang
National Engineering Laboratory for AIDS Vaccine, Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences Jilin University Changchun China
2 shared publications
Latest Publications
- Open Access
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46264
Dietary magnesium intake as modifier of the association between vitamin D deficiency and risk of anemia in the US children aged 2–14 years: A cross-sectional study
Vitamin D deficiency and magnesium deficiency are both associated with an increased risk of anemia. However, the impact of dietary magnesium intake on the relationship between vitamin D deficiency and anemia risk has yet to be determined. In this study, 11,471 children aged 2 to 14 years were enrolled using data from the National Health and Nutrition Examination Survey 2005 to 2018. The participants were divided into low and high magnesium intake groups based on a quantile cutoff of < 208.5 and ≥ 208.5 mg/d, respectively. Participants who were vitamin D deficiency had an increased risk of anemia (odds ratio = 1.492, 95% confidence intervals: 1.072–2.077). The incidence of anemia differed in low-dietary magnesium intake and high-dietary magnesium intake groups (odds ratio, 95% confidence interval: 1.992, 1.264–3.139 vs 0.934, 0.564–1.548, respectively), indicating an interaction between vitamin D deficiency and dietary magnesium intake in anemia risk ( P = .009), which suggests that a magnesium-rich diet may reduce the risk of vitamin D deficiency-induced anemia. the findings highlight the synergistic effect of low-dietary magnesium intake and vitamin D deficiency on the increased risk of anemia in children.
- 12 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (50) , e46264
Open AccessDietary magnesium intake as modifier of the association between vitamin D deficiency and risk of anemia in the US children aged 2–14 years: A cross-sectional study
Vitamin D deficiency and magnesium deficiency are both associated with an increased risk of anemia. However, the impact of dietary magnesium intake on the relationship between vitamin D deficiency and anemia risk has yet to be determined. In this study, 11,471 children aged 2 to 14 years were enrolled using data from the National Health and Nutrition Examination Survey 2005 to 2018. The participants were divided into low and high magnesium intake groups based on a quantile cutoff of < 208.5 and ≥ 208.5 mg/d, respectively. Participants who were vitamin D deficiency had an increased risk of anemia (odds ratio = 1.492, 95% confidence intervals: 1.072–2.077). The incidence of anemia differed in low-dietary magnesium intake and high-dietary magnesium intake groups (odds ratio, 95% confidence interval: 1.992, 1.264–3.139 vs 0.934, 0.564–1.548, respectively), indicating an interaction between vitamin D deficiency and dietary magnesium intake in anemia risk ( P = .009), which suggests that a magnesium-rich diet may reduce the risk of vitamin D deficiency-induced anemia. the findings highlight the synergistic effect of low-dietary magnesium intake and vitamin D deficiency on the increased risk of anemia in children.
- Open Access
- 16 September 2025
- Published by Wiley in Molecular Oncology
- Vol. 20 (2) , 555-572
Inhibition of CDK 9 enhances AML cell death induced by combined venetoclax and azacitidine
Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates between 20% and 60%, and responses are not durable, highlighting the need for new therapies. Here, we report elevated mTORC1 signaling in AraC‐resistant AML cell lines, primary AML patient samples, and patient‐derived xenograft (PDX) AML cells derived from patients at relapse postchemotherapy. The CDK9 inhibitor AZD4573 suppresses mTORC1 signaling and downregulates c‐MYC and MCL‐1, inducing AraC‐resistant AML cell death. AZD4573 in combination with VEN + AZA significantly increases AML cell death compared to any of the two‐drug combinations and suppresses AML progenitor cells but spares normal hematopoietic progenitor cells. The efficacy of this triple combination remains even with a 10‐fold reduction of VEN concentration. The roles of MCL‐1 and c‐MYC in the three‐drug combination were confirmed by knockdown. This study demonstrates that AZD4573 enhances the activity of VEN + AZA against AraC‐resistant AML by downregulating c‐MYC and MCL‐1 and to a lesser extent cellular respiration.
- 16 September 2025
- Published by Wiley in Molecular Oncology
- Vol. 20 (2) , 555-572
Open AccessInhibition of CDK 9 enhances AML cell death induced by combined venetoclax and azacitidine
Relapsed/refractory (R/R) disease is a major hurdle to long‐term survival of acute myeloid leukemia (AML) patients treated with intensive cytarabine (AraC)‐based chemotherapy. R/R AML salvage treatment with venetoclax (VEN) + azacitidine (AZA) results in overall response rates between 20% and 60%, and responses are not durable, highlighting the need for new therapies. Here, we report elevated mTORC1 signaling in AraC‐resistant AML cell lines, primary AML patient samples, and patient‐derived xenograft (PDX) AML cells derived from patients at relapse postchemotherapy. The CDK9 inhibitor AZD4573 suppresses mTORC1 signaling and downregulates c‐MYC and MCL‐1, inducing AraC‐resistant AML cell death. AZD4573 in combination with VEN + AZA significantly increases AML cell death compared to any of the two‐drug combinations and suppresses AML progenitor cells but spares normal hematopoietic progenitor cells. The efficacy of this triple combination remains even with a 10‐fold reduction of VEN concentration. The roles of MCL‐1 and c‐MYC in the three‐drug combination were confirmed by knockdown. This study demonstrates that AZD4573 enhances the activity of VEN + AZA against AraC‐resistant AML by downregulating c‐MYC and MCL‐1 and to a lesser extent cellular respiration.
- Open Access
- 24 January 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (4) , e40652
Three cases of hemoglobin M disease in a family lineage: Case report and literature review
Rationale: This study presents a case of hemoglobin M disease (HMD), a rare inherited disorder characterized by persistent cyanosis and hypoxemia, observed across 3 generations within a single family. The diagnosis of HMD poses significant challenges, particularly in asymptomatic individuals, due to its rarity and the subtlety of its symptoms. Notably, there is a scarcity of reports on methemoglobinemia in pediatric populations, which further complicates early detection and intervention. The primary objectives of this study are to enhance awareness of HMD, to advocate for accurate diagnosis and timely treatment, and to underscore the necessity of considering this condition in patients with a familial history of cyanosis. Patient concerns: A 6-year-old boy presented to our hospital with fatigue and cyanosis in his lips and mouth. Both the child’s mother and grandfather had a history of similar symptoms since their childhood. Diagnoses: Diagnosis of hemoglobin M disease. Interventions: The patient was treated with vitamin C. Outcomes: Genetic testing revealed that the patient and her mother carried the c.190C > T mutation, leading to the p.H63Y amino acid change linked to the methemoglobin (MetHb) mutation. Despite undergoing vitamin C therapy, the patient’s symptoms of cyanosis and fatigue persisted. Lessons: Hemoglobin M disease can be readily diagnosed with a delay. Methemoglobinemia should be considered in patients with a family history of cyanosis but no cardiopulmonary disease. Hospital blood gas analysis should include a protocol for detecting methemoglobin, and genetic testing can help confirm the diagnosis.
- 24 January 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (4) , e40652
Open AccessThree cases of hemoglobin M disease in a family lineage: Case report and literature review
Rationale: This study presents a case of hemoglobin M disease (HMD), a rare inherited disorder characterized by persistent cyanosis and hypoxemia, observed across 3 generations within a single family. The diagnosis of HMD poses significant challenges, particularly in asymptomatic individuals, due to its rarity and the subtlety of its symptoms. Notably, there is a scarcity of reports on methemoglobinemia in pediatric populations, which further complicates early detection and intervention. The primary objectives of this study are to enhance awareness of HMD, to advocate for accurate diagnosis and timely treatment, and to underscore the necessity of considering this condition in patients with a familial history of cyanosis. Patient concerns: A 6-year-old boy presented to our hospital with fatigue and cyanosis in his lips and mouth. Both the child’s mother and grandfather had a history of similar symptoms since their childhood. Diagnoses: Diagnosis of hemoglobin M disease. Interventions: The patient was treated with vitamin C. Outcomes: Genetic testing revealed that the patient and her mother carried the c.190C > T mutation, leading to the p.H63Y amino acid change linked to the methemoglobin (MetHb) mutation. Despite undergoing vitamin C therapy, the patient’s symptoms of cyanosis and fatigue persisted. Lessons: Hemoglobin M disease can be readily diagnosed with a delay. Methemoglobinemia should be considered in patients with a family history of cyanosis but no cardiopulmonary disease. Hospital blood gas analysis should include a protocol for detecting methemoglobin, and genetic testing can help confirm the diagnosis.
- 24 June 2024
- Published by Elsevier in Leukemia Research
- Vol. 144, 107547
Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML
- 24 June 2024
- Published by Elsevier in Leukemia Research
- Vol. 144, 107547
Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML
- 12 December 2023
- Published by Springer Nature in Investigational New Drugs
- Vol. 42 (1) , 70-79
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Summary In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukemia (AML). However, there is still ample opportunity for enhancing efficacy. The Wee1 inhibitor adavosertib (ADA) shows promise for the treatment of AML. Based on the effect of drugs on DNA damage, we conducted a combination study involving ADA and fimepinostat (CUDC-907), a dual inhibitor of PI3K and histone deacetylase (HDAC). We observed that the combination of CUDC-907 and ADA exhibited a synergistic effect in enhancing the antileukemic activity in both AML cell lines and primary patient samples, demonstrating through flow cytometry analysis and MTT assay, respectively. Additionally, our study revealed that CUDC-907 has the ability to augment ADA-induced DNA damage, as determined by the measurement of γH2AX levels and the implementation of the alkaline comet assay. Through the utilization of western blotting analyses, targeted inhibitors, and ectopic overexpression, we propose that the downregulation of Wee1, CHK1, RNR, and c-Myc are the potential mechanisms. Our data support the development of ADA in combination with CUDC-907 for the treatment of AML.
- 12 December 2023
- Published by Springer Nature in Investigational New Drugs
- Vol. 42 (1) , 70-79
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Summary In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukemia (AML). However, there is still ample opportunity for enhancing efficacy. The Wee1 inhibitor adavosertib (ADA) shows promise for the treatment of AML. Based on the effect of drugs on DNA damage, we conducted a combination study involving ADA and fimepinostat (CUDC-907), a dual inhibitor of PI3K and histone deacetylase (HDAC). We observed that the combination of CUDC-907 and ADA exhibited a synergistic effect in enhancing the antileukemic activity in both AML cell lines and primary patient samples, demonstrating through flow cytometry analysis and MTT assay, respectively. Additionally, our study revealed that CUDC-907 has the ability to augment ADA-induced DNA damage, as determined by the measurement of γH2AX levels and the implementation of the alkaline comet assay. Through the utilization of western blotting analyses, targeted inhibitors, and ectopic overexpression, we propose that the downregulation of Wee1, CHK1, RNR, and c-Myc are the potential mechanisms. Our data support the development of ADA in combination with CUDC-907 for the treatment of AML.
- Open Access
- 31 May 2023
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 13 (6) , 561-567
Baicalin inhibits the replication of the hepatitis B virus by targeting TRIM25
- 31 May 2023
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 13 (6) , 561-567
Open AccessBaicalin inhibits the replication of the hepatitis B virus by targeting TRIM25
- Open Access
Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (FLT3-ITD) mutations occur in about 25% of all acute myeloid leukemia (AML) patients and confer a poor prognosis. FLT3 inhibitors have been developed to treat patients with FLT3-mutated AML and have shown promise, though the acquisition of resistance occurs, highlighting the need for combination therapies to prolong the response to FLT3 inhibitors. In this study, we investigated the selective Mcl-1 inhibitor AZD5991 in combination with the FLT3 inhibitors gilteritinib and MRX-2843. The combinations synergistically induce apoptosis in AML cell lines and primary patient samples. The FLT3 inhibitors downregulate c-Myc transcripts through the suppression of the MEK/ERK and JAK2/STAT5 pathways, resulting in the decrease in c-Myc protein. This suppression of c-Myc plays an important role in the antileukemic activity of AZD5991. Interestingly, the suppression of c-Myc enhances AZD5991-inudced cytochrome c release and the subsequent induction of apoptosis. AZD5991 enhances the antileukemic activity of the FLT3 inhibitors gilteritinib and MRX-2843 against FLT3-mutated AML in vitro, warranting further development.
Open AccessInhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (FLT3-ITD) mutations occur in about 25% of all acute myeloid leukemia (AML) patients and confer a poor prognosis. FLT3 inhibitors have been developed to treat patients with FLT3-mutated AML and have shown promise, though the acquisition of resistance occurs, highlighting the need for combination therapies to prolong the response to FLT3 inhibitors. In this study, we investigated the selective Mcl-1 inhibitor AZD5991 in combination with the FLT3 inhibitors gilteritinib and MRX-2843. The combinations synergistically induce apoptosis in AML cell lines and primary patient samples. The FLT3 inhibitors downregulate c-Myc transcripts through the suppression of the MEK/ERK and JAK2/STAT5 pathways, resulting in the decrease in c-Myc protein. This suppression of c-Myc plays an important role in the antileukemic activity of AZD5991. Interestingly, the suppression of c-Myc enhances AZD5991-inudced cytochrome c release and the subsequent induction of apoptosis. AZD5991 enhances the antileukemic activity of the FLT3 inhibitors gilteritinib and MRX-2843 against FLT3-mutated AML in vitro, warranting further development.
- 1 January 2022
- Published by Elsevier in Experimental Hematology
- Vol. 105, 39-49
Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance
- 1 January 2022
- Published by Elsevier in Experimental Hematology
- Vol. 105, 39-49
Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance
- Open Access
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 12
KDM4C contributes to cytarabine resistance in acute myeloid leukemia via regulating the miR-328-3p/CCND2 axis through MALAT1
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm, in which relapse due to drug resistance is the main cause for treatment failure and the disease progression. In this study, we aimed to investigate the molecular mechanism of KDM4C-dependent MALAT1/miR-328-3p/CCND2 axis in cytarabine (Ara-C) resistance in the context of AML. Bioinformatics analysis was performed to predict the targeting relationships among KDM4C, MALAT1, miR-328-3p, and CCND2 in AML, which were validated with chromatin immunoprecipitation and dual-luciferase reporter assay. Methylation-specific polymerase chain reaction was conducted to detect the methylation of MALAT1 promoter. After conducting gain- and loss-of-function assays, we investigated the effect of KDM4C on cell Ara-C resistance. A NOD/SCID mouse model was established to further investigate the roles of KDM4C/MALAT1/miR-328-3p/CCND2 in Ara-C resistant AML cells. KDM4C expression was upregulated in AML. KDM4C upregulation promoted the demethylation in the promoter region of MALAT1 to increase its expression, MALAT1 targeted and inhibited miR-328-3p expression, enhancing the Ara-C resistance of HL-60/A. miR-328-3p targeted and suppressed the expression of CCND2 in HL-60/A to inhibit the Ara-C resistance. Mechanistically, KDM4C regulated miR-328-3p/CCND2 through MALAT1, resulting in Ara-C resistance in AML. Findings in an in vivo xenograft NOD/SCID mouse model further confirmed the contribution of KDM4C/MALAT1/miR-328-3p/CCND2 in the Ara-C resistant AML. Our study demonstrated that KDM4C may up-regulate MALAT1 expression, which decreases the expression of miR-328-3p. The downregulation of miR-328-3p increased the level of CCND2, which induced the Ara-C resistance in AML.
- 1 January 2021
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 12
Open AccessKDM4C contributes to cytarabine resistance in acute myeloid leukemia via regulating the miR-328-3p/CCND2 axis through MALAT1
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm, in which relapse due to drug resistance is the main cause for treatment failure and the disease progression. In this study, we aimed to investigate the molecular mechanism of KDM4C-dependent MALAT1/miR-328-3p/CCND2 axis in cytarabine (Ara-C) resistance in the context of AML. Bioinformatics analysis was performed to predict the targeting relationships among KDM4C, MALAT1, miR-328-3p, and CCND2 in AML, which were validated with chromatin immunoprecipitation and dual-luciferase reporter assay. Methylation-specific polymerase chain reaction was conducted to detect the methylation of MALAT1 promoter. After conducting gain- and loss-of-function assays, we investigated the effect of KDM4C on cell Ara-C resistance. A NOD/SCID mouse model was established to further investigate the roles of KDM4C/MALAT1/miR-328-3p/CCND2 in Ara-C resistant AML cells. KDM4C expression was upregulated in AML. KDM4C upregulation promoted the demethylation in the promoter region of MALAT1 to increase its expression, MALAT1 targeted and inhibited miR-328-3p expression, enhancing the Ara-C resistance of HL-60/A. miR-328-3p targeted and suppressed the expression of CCND2 in HL-60/A to inhibit the Ara-C resistance. Mechanistically, KDM4C regulated miR-328-3p/CCND2 through MALAT1, resulting in Ara-C resistance in AML. Findings in an in vivo xenograft NOD/SCID mouse model further confirmed the contribution of KDM4C/MALAT1/miR-328-3p/CCND2 in the Ara-C resistant AML. Our study demonstrated that KDM4C may up-regulate MALAT1 expression, which decreases the expression of miR-328-3p. The downregulation of miR-328-3p increased the level of CCND2, which induced the Ara-C resistance in AML.
- 19 June 2017
- Published by Springer Nature in International Urology and Nephrology
- Vol. 49 (10) , 1801-1807
Smoking as a risk factor for diabetic nephropathy: a meta-analysis
Previous studies have investigated the connection between diabetic nephropathy and smoking, and reported widely varying rates. This study aimed to systematically analyze the impact of smoking on diabetic nephropathy. We searched the PubMed and EMBASE electronic databases to identify relevant English-language studies published up to March 2016. Eligible studies were selected using inclusion and exclusion criteria. Data for each study were extracted independently by two authors. The homogeneity of the effect size across the studies was tested. Odds ratio (OR) was calculated by using the random-effect model. Sensitivity analysis was performed to reduce heterogeneity, and publication biases were examined. A total of 21 eligible studies were selected and pooled analyzed. No significant differences in demographic characteristics were found between patients with diabetic nephropathy and those with non-diabetic nephropathy. Significant heterogeneity across studies was found except those of diabetes mellitus controls. The aggregate OR of smoking in the patients with diabetic nephropathy in comparison with those with non-diabetic nephropathy was 1.70 (95% confidence interval 1.48–1.95). No evidence of publication bias was found. Our findings indicate that smoking is a significant risk factor for diabetic nephropathy in diabetic patients.
- 19 June 2017
- Published by Springer Nature in International Urology and Nephrology
- Vol. 49 (10) , 1801-1807
Smoking as a risk factor for diabetic nephropathy: a meta-analysis
Previous studies have investigated the connection between diabetic nephropathy and smoking, and reported widely varying rates. This study aimed to systematically analyze the impact of smoking on diabetic nephropathy. We searched the PubMed and EMBASE electronic databases to identify relevant English-language studies published up to March 2016. Eligible studies were selected using inclusion and exclusion criteria. Data for each study were extracted independently by two authors. The homogeneity of the effect size across the studies was tested. Odds ratio (OR) was calculated by using the random-effect model. Sensitivity analysis was performed to reduce heterogeneity, and publication biases were examined. A total of 21 eligible studies were selected and pooled analyzed. No significant differences in demographic characteristics were found between patients with diabetic nephropathy and those with non-diabetic nephropathy. Significant heterogeneity across studies was found except those of diabetes mellitus controls. The aggregate OR of smoking in the patients with diabetic nephropathy in comparison with those with non-diabetic nephropathy was 1.70 (95% confidence interval 1.48–1.95). No evidence of publication bias was found. Our findings indicate that smoking is a significant risk factor for diabetic nephropathy in diabetic patients.